Chinese engineers have built a bioelectronic comb that regrew nearly all lost hair on bald mice within four weeks, according to a study published in Nature Communications.
The device, named Detangle, combines low‑level electrical stimulation with two nucleic‑acid treatments delivered during each combing stroke. In mice with hormone‑induced androgenetic alopecia, bald patches reached 97.9 percent hair coverage after 28 days of treatment every three days, researchers at Beihang University and the City University of Hong Kong reported.
By comparison, daily minoxidil achieved roughly 70 percent coverage and finasterid about 50 percent in the same model. The study authors said that more than 1.5 billion people worldwide are affected by androgenetic alopecia, in which the hormone dihydrotestosterone (DHT) plays a central role by shrinking hair follicles.
A comb with electrified teeth regrew nearly all lost hair on balding skin in a month. The device, called Detangle, was built by engineers at Beihang University in Beijing and described in Nature Communications. Its teeth carry tiny electrodes set at different heights, plus… pic.twitter.com/Fp6qpw23Ax
How the comb works
Detangle’s teeth carry tiny electrodes set at different heights. As the comb moves through the hair, the uneven teeth create an electric field that penetrates about nine times deeper than surface electrodes, the study authors wrote. The plasmid prompts production of a growth factor called VEGF-A, which builds new blood vessels around the follicles.
The siRNA silences the enzyme that makes DHT, the hormone that shrinks follicles in pattern baldness. In marker‑dye tests, the comb drove material to 660 micrometers depth in one second, versus 74 micrometers for topical application alone. The electrical stimulation also facilitated uptake into hair follicle cells.
Results and safety in mice
Male mice were shaved and given testosterone to induce androgenetic alopecia on their backs. One group received the full Detangle treatment — electrical stimulation plus both nucleic acids — every three days for 28 days. Control groups received minoxidil, finasterid, electrical stimulation alone, or no treatment.
At the end of the period, the Detangle group showed near‑complete hair regrowth. Minoxidil reached about 70 percent coverage, finasterid about 50 percent, and electrical stimulation alone roughly 40 percent, according to N Tv.
Tissue analysis showed increased follicular density, improved local blood flow, and activation of the Wnt/beta-catenin signaling pathway, which influences the renewal of hair follicles. No skin irritation or inflammation markers were observed in treated mice. The combination of both molecules achieved more hair growth than the individual delivery of each molecule alone.
Deeper delivery measured in marker tests
The electrical stimulation also increased uptake into hair‑follicle cells, according to the same paper.

Mechanism combines two nucleic‑acid agents
The device delivers a VEGFA plasmid that encodes the growth factor VEGF‑A to spur new blood‑vessel formation around follicles, and an siRNA targeting the SRD5A2 gene to suppress the enzyme that converts testosterone into DHT, the hormone that shrinks follicles in pattern baldness, the researchers stated.
From mice to humans
The researchers and independent experts emphasized that the work remains preclinical. The baldness was experimentally generated on the back skin of mice and is not to be equated with the progressive baldness in humans over years.
Long‑term safety of repeated delivery of DNA and RNA into the scalp remains unclarified, and whether it can be used effectively and safely in humans must be shown by further investigations including clinical trials.
Beihang University ranks among China’s elite Project 985, Project 211 and Double First‑Class institutions and is directly affiliated with the Ministry of Industry and Information Technology. The university operates one national laboratory, nine national key laboratories — including four defense‑technology key laboratories — and six national engineering centers, giving it deep infrastructure for interdisciplinary bioengineering and medical‑device development.
The team suggested the combing‑triggered electroporation platform could eventually be adapted for other dermatological conditions where deep drug delivery is a barrier.
More on Nature Communications
Worth a look